They are developing a next generation anti-PD-L1 t-haNK cell line equipped with inducible safety switch features to remove the need for irradiation. Also, modifications that could limit rejection after infusion, as well as cytokine-induced memory-like expansion.
Personally, I think they should have switched some years ago to developing iPSC-derived CAR (and/or TCR) cell therapies. One benefit of using iPSCs is that the cell lines can be differentiated into any cell type of the body.
Market Data 
Markets 
AI
